An Analysis of Parkinson’s Disease Medication Treatment Patterns among Medicaid Patients
Objective: To describe patient demographic and medication utilization patterns within a state Medicaid program for patients diagnosed with Parkinson’s disease (PD). Background: Little is known…Parkinson’s Disease in Israel – Initial Symptoms and Comorbidities from 20 years of Follow Up in a Population-based Cohort
Objective: To describe the epidemiology of Parkinson’s disease (PD) in Israel during a 20-year period, 2000–2019, and to characterize initial symptoms and comorbidities of PD…Effects of Different Side-of-onset on Symptoms, Progression, and Prognosis in Parkinson’s Disease
Objective: We conducted an ambispective cohort study, with the largest number of involved patients for now, to assess whether the different side-of-onset could affect the…Short- and Long-term Healthcare Resource Utilization in Parkinson’s Disease – 20 years of Follow Up in a Population-based Cohort
Objective: To assess Parkinson’s disease (PD) burden by means of healthcare resource utilization (HCRU) and clinical outcomes in Israeli PD patients during 20-year period ,2000…Not so simple: the challenge of developing a non-motor symptoms app (NMS Assist) for people with Parkinson’s (PwP)
Objective: To evaluate usability and identify the challenges for PwP when using NMS Assist. Background: There is great potential for mHealth technologies, such as apps,…Evaluation of Cortical Excitability in Huntington’s Disease and Parkinson’s Disease
Objective: To evaluate the cortical excitability difference in Huntington's disease (HD) and Parkinson's disease (PD) using paired-pulse transcranial magnetic stimulation (TMS). Background: TMS is useful…Repetitive transcranial magnetic stimulation (rTMS) fails to improve cognition in patients with Parkinson’s disease: a meta-analysis of randomized controlled trials
Objective: This study aimed to evaluate the effects of rTMS for improving cognition of PD patients. Background: Up to 20%–50% of patients with Parkinson’s disease…Moderately frequent and private variants in PRKN are associated with late-onset Parkinson’s disease
Objective: We hypothesized that heterozygosity for rare coding variants in PRKN, PINK1 or PARK7 might also represent a risk factor for sporadic late-onset PD.[4] Background:…PRKN Positive Parkinson’s Disease Masked as Dopa-Responsive Dystonia
Objective: To report a Parkinson’s disease (PD) patient with PRKN mutation initially diagnosed with dopa-responsive dystonia (DRD), unmasked after developing signs of parkinsonian disease progression.…Bumetanide to treat Parkinson’s disease patients suffering from freezing of gait resistant to both dopamine replacement treatment and subthalamic deep brain stimulation: an open-label pilot study (BumFOG)
Objective: to investigate the effects of bumetanide in Parkinson's disease (PD) patients suffering from freezing of gait (FOG) resistant to dopamine replacement therapy and subthalamic…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 9
- Next Page »